Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sheeba K Thomas

Showing results (21-30 of 114) with videos related to

Pageof 12
Sort By:
Haematologica|August 16, 2019
Phase I/Ib study of carfilzomib and panobinostat with or without dexamethasone in patients with relapsed/refractory multiple myelomaElisabet E Manasanch, Jatin J Shah, Hans C Lee, et al.
American Journal of Hematology|September 7, 2019
A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myelomaHans C Lee, Jatin J Shah, Lei Feng, et al.
Hepatology International|December 8, 2022
Hepatitis B virus reactivation in patients with past HBV infection receiving anti-CD38 monoclonal antibodiesChia-Yu Chiu, Krina Patel, Sheeba K Thomas, et al.
Cancer|March 26, 2011
Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapyValerie Reed, Jatin Shah, L Jeffery Medeiros, et al.
The Journal of Pain|July 27, 2015
Measuring Therapy-Induced Peripheral Neuropathy: Preliminary Development and Validation of the Treatment-Induced Neuropathy Assessment ScaleTito R Mendoza, Xin Shelley Wang, Loretta A Williams, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 11, 2017
Additional-structural-chromosomal aberrations are associated with inferior clinical outcome in patients with hyperdiploid multiple myeloma: a single-institution experienceAdrian A Carballo-Zarate, L Jeffrey Medeiros, Lianghua Fang, et al.
Human Pathology|October 16, 2022
Lymphoplasmacytic lymphoma with IgG or IgA paraprotein: a study of 29 cases including cases that can mimic plasma cell neoplasmsLianqun Qiu, Okechukwu V Nwogbo, L Jeffrey Medeiros, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 1, 2017
Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletionSuyang Hao, Pei Lin, L Jeffrey Medeiros, et al.
Cancer Chemotherapy and Pharmacology|October 24, 2013
Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myelomaSheeba K Thomas, Alexander Suvorov, Lucien Noens, et al.
Blood Cancer Journal|October 3, 2019
A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myelomaHans C Lee, Jatin J Shah, Lei Feng, et al.
Pageof 12

Showing results (21-30 of 114) with videos related to

Sort By:
Pageof 12
Haematologica|August 16, 2019
Phase I/Ib study of carfilzomib and panobinostat with or without dexamethasone in patients with relapsed/refractory multiple myelomaElisabet E Manasanch, Jatin J Shah, Hans C Lee, et al.
American Journal of Hematology|September 7, 2019
A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myelomaHans C Lee, Jatin J Shah, Lei Feng, et al.
Hepatology International|December 8, 2022
Hepatitis B virus reactivation in patients with past HBV infection receiving anti-CD38 monoclonal antibodiesChia-Yu Chiu, Krina Patel, Sheeba K Thomas, et al.
Cancer|March 26, 2011
Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapyValerie Reed, Jatin Shah, L Jeffery Medeiros, et al.
The Journal of Pain|July 27, 2015
Measuring Therapy-Induced Peripheral Neuropathy: Preliminary Development and Validation of the Treatment-Induced Neuropathy Assessment ScaleTito R Mendoza, Xin Shelley Wang, Loretta A Williams, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 11, 2017
Additional-structural-chromosomal aberrations are associated with inferior clinical outcome in patients with hyperdiploid multiple myeloma: a single-institution experienceAdrian A Carballo-Zarate, L Jeffrey Medeiros, Lianghua Fang, et al.
Human Pathology|October 16, 2022
Lymphoplasmacytic lymphoma with IgG or IgA paraprotein: a study of 29 cases including cases that can mimic plasma cell neoplasmsLianqun Qiu, Okechukwu V Nwogbo, L Jeffrey Medeiros, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 1, 2017
Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletionSuyang Hao, Pei Lin, L Jeffrey Medeiros, et al.
Cancer Chemotherapy and Pharmacology|October 24, 2013
Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myelomaSheeba K Thomas, Alexander Suvorov, Lucien Noens, et al.
Blood Cancer Journal|October 3, 2019
A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myelomaHans C Lee, Jatin J Shah, Lei Feng, et al.
Pageof 12